Fig. 2. m⁶A is required for cytokine-induced ILC2 responses.

a,b, Representative flow cytometry (a) and quantification (b) of the percentage of Ki-67⁺ cells and total cell number of liver CD45⁺Lin⁻Thy1⁺NK1.1⁺ ILC1s after 3 d of IL-12 + IL-18 treatment in Mettl3^Δ/Δ and Mettl3^fl/fl mice that received three doses of tamoxifen before cytokine treatment; NS P = 0.5363 (left) and NS P = 0.7907 (right; b). c,d, Representative flow cytometry (c) and quantification (d) of the percentage of Ki-67⁺ cells and total cell number of small intestine CD45⁺Lin⁻Thy1⁺RORγt⁺ ILC3s after 3 d of IL-1β + IL-23 treatment in Mettl3^Δ/Δ and Mettl3^fl/fl mice that received three doses of tamoxifen before cytokine treatment; NS P = 0.8134 (left) and NS P = 0.6416 (right; d). e, Representative immunofluorescence imaging and quantification of the percentage of Ki-67⁺ small intestine CD3⁻KLRG1⁺ ILC2s after 3 d of IL-25 treatment in Mettl3^Δ/Δ and Mettl3^fl/fl mice that received three doses of tamoxifen before cytokine treatment; **P = 0.0052; scale bar, 50 μm. f, RT–qPCR analysis of Il5 and Il13 mRNAs in tissue from the small intestine of mice as in e; ** P = 0.0027 (left) and **P = 0.0004 (right). g,h, Representative flow cytometry (lung; g) and quantification (lung and MLNs; h) of CD45⁺Lin⁻Thy1⁺ST2⁻KLRG1^hi iILC2s of the mice as in e. In h, **P = 0.0027 (left) and ***P = 0.0096 (right). i, Ratios of wild-type B6.SJL (WT) and Mettl3^Δ/Δ iILC2s in the lungs on day 16 after transfer of wild-type and Mettl3^Δ/Δ intestinal ILC2s at a ratio of 1:1 into Rag2^−/−Il2rg^−/− recipient mice that received three doses of tamoxifen from days 5 to 9 and three injections of IL-25 from days 13 to 15 after transfer. Data were analyzed by unpaired two-tailed t-test; n = 3–5 in b, d, e, f, h and i. Data are shown as mean ± s.d. Results are representative of three independent experiments.